SeaStar Medical, Inc.

SeaStar Medical is a clinical-stage immunotherapy company developing the Selective Cytopheretic Device (SCD), a patented therapeutic platform designed to treat destructive hyperinflammatory responses in critically ill patients. The SCD selectively targets and neutralizes highly activated neutrophils and monocytes responsible for cytokine storms—uncontrolled inflammatory cascades triggered by trauma, infection, or surgery that can lead to multiorgan failure and death in ICU settings. The device integrates seamlessly into existing hemodialysis delivery systems, offering a disease-modifying approach to restore immune balance without requiring standalone infrastructure. SeaStar's technology addresses a significant clinical gap: there are currently no FDA-approved therapeutic options specifically designed to calm hyperinflammation in this patient population. The company's clinical evidence supports that SCD therapy may reduce ICU length of stay, decrease dialysis dependency, and improve survival outcomes. The device is positioned for use in critical care and intensive care units treating sepsis, post-surgical complications, and trauma-induced inflammatory responses. SeaStar Medical is headquartered in Denver, Colorado, and is focused on advancing the critical-care treatment paradigm through robust scientific validation and regulatory pathways.